Company Filing History:
5 out of 470 
1 out of 1,380 
Years Active: 2015-2022
Title: The Innovative Contributions of Daniel P. Regan
Introduction
Daniel P. Regan is a notable inventor based in Fort Collins, Colorado. He has made significant contributions to the field of immunology and cancer treatment through his innovative patents. With a total of 5 patents, Regan's work focuses on enhancing immune responses and developing effective cancer therapies.
Latest Patents
One of Regan's latest patents is for "Optimized Cancer Stem Cell Vaccines." This invention provides cancer stem cell vaccines that are useful for treating or preventing various tumors. It also includes methods for producing cancer stem cells and their antigens, as well as creating vaccine adjuvants with enhanced activity for use with these stem cell vaccines. Another significant patent is titled "Compositions and Methods for Enhanced Innate Immunity." This patent discloses an immunogenic composition that includes cationic liposomes, a mixture of toll-like receptor 3 (TLR3) and toll-like receptor 9 (TLR9) ligands, and a cellular adhesion agent. The methods described in this patent aim to induce a non-specific innate immune response at mucosal surfaces and enhance the immune response to antigens when administered to mammals.
Career Highlights
Throughout his career, Daniel P. Regan has worked with esteemed institutions such as the Colorado State University Research Foundation and the University of Colorado. His research has significantly advanced the understanding of immune responses and cancer treatment methodologies.
Collaborations
Regan has collaborated with notable colleagues, including Steven Dow and Amanda Guth. Their combined expertise has contributed to the success of various research projects and innovations in the field.
Conclusion
Daniel P. Regan's innovative work in immunology and cancer treatment has led to the development of important patents that enhance immune responses and provide new therapeutic options. His contributions continue to impact the scientific community and improve patient outcomes.